Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 50.95
(1.6%)
EUR 50.95
(1.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 256.39 Million EUR | -27.89% |
| 2022 | 355.55 Million EUR | 37.08% |
| 2021 | 259.36 Million EUR | 30.98% |
| 2020 | 198.02 Million EUR | 6.65% |
| 2019 | 185.68 Million EUR | 66.37% |
| 2018 | 111.6 Million EUR | 8.86% |
| 2017 | 102.52 Million EUR | 2.72% |
| 2016 | 99.8 Million EUR | 21.5% |
| 2015 | 82.14 Million EUR | -20.13% |
| 2014 | 102.85 Million EUR | 12.45% |
| 2013 | 91.45 Million EUR | -4.65% |
| 2012 | 95.91 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 254.88 Million EUR | -0.06% |
| 2024 Q2 | 374.56 Million EUR | 46.96% |
| 2023 FY | 255.03 Million EUR | -28.27% |
| 2023 Q2 | 378.48 Million EUR | 19.62% |
| 2023 Q1 | 316.39 Million EUR | -11.01% |
| 2023 Q3 | 276.08 Million EUR | -27.05% |
| 2023 Q4 | 255.03 Million EUR | -7.63% |
| 2022 Q2 | 389.3 Million EUR | 21.98% |
| 2022 FY | 355.55 Million EUR | 37.08% |
| 2022 Q4 | 355.55 Million EUR | 8.01% |
| 2022 Q3 | 329.18 Million EUR | -15.44% |
| 2022 Q1 | 319.16 Million EUR | 23.05% |
| 2021 Q2 | 237.9 Million EUR | 22.61% |
| 2021 Q1 | 194.03 Million EUR | -3.34% |
| 2021 Q4 | 259.36 Million EUR | 11.78% |
| 2021 Q3 | 232.03 Million EUR | -2.47% |
| 2021 FY | 259.36 Million EUR | 30.98% |
| 2020 Q4 | 200.73 Million EUR | 4.41% |
| 2020 FY | 198.02 Million EUR | 6.65% |
| 2020 Q3 | 192.25 Million EUR | 0.35% |
| 2020 Q2 | 191.58 Million EUR | 0.65% |
| 2020 Q1 | 190.34 Million EUR | 0.81% |
| 2019 Q2 | 149.81 Million EUR | 12.46% |
| 2019 Q4 | 188.82 Million EUR | 36.47% |
| 2019 Q1 | 133.21 Million EUR | 15.61% |
| 2019 FY | 185.68 Million EUR | 66.37% |
| 2019 Q3 | 138.36 Million EUR | -7.64% |
| 2018 Q1 | 108.69 Million EUR | 1.87% |
| 2018 Q3 | 115.05 Million EUR | -3.42% |
| 2018 Q2 | 119.13 Million EUR | 9.6% |
| 2018 FY | 111.6 Million EUR | 8.86% |
| 2018 Q4 | 115.22 Million EUR | 0.15% |
| 2017 Q4 | 106.69 Million EUR | 8.66% |
| 2017 FY | 102.52 Million EUR | 2.72% |
| 2017 Q3 | 98.19 Million EUR | -13.02% |
| 2017 Q2 | 112.88 Million EUR | 0.86% |
| 2017 Q1 | 111.92 Million EUR | 7.16% |
| 2016 FY | 99.8 Million EUR | 21.5% |
| 2016 Q3 | 92.31 Million EUR | -10.46% |
| 2016 Q2 | 103.09 Million EUR | 12.77% |
| 2016 Q1 | 91.41 Million EUR | -7.72% |
| 2016 Q4 | 104.44 Million EUR | 13.14% |
| 2015 Q1 | 96.74 Million EUR | -5.94% |
| 2015 FY | 82.14 Million EUR | -20.13% |
| 2015 Q4 | 99.06 Million EUR | -0.8% |
| 2015 Q3 | 99.86 Million EUR | -5.19% |
| 2015 Q2 | 105.32 Million EUR | 8.87% |
| 2014 Q2 | 96.48 Million EUR | 11.38% |
| 2014 Q1 | 86.62 Million EUR | -5.29% |
| 2014 FY | 102.85 Million EUR | 12.45% |
| 2014 Q4 | 102.85 Million EUR | 13.22% |
| 2014 Q3 | 90.83 Million EUR | -5.85% |
| 2013 Q3 | 95.86 Million EUR | -0.12% |
| 2013 FY | 91.45 Million EUR | -4.65% |
| 2013 Q4 | 91.45 Million EUR | -4.6% |
| 2013 Q1 | 92.51 Million EUR | -3.55% |
| 2013 Q2 | 95.98 Million EUR | 3.75% |
| 2012 Q4 | 95.91 Million EUR | 0.0% |
| 2012 FY | 95.91 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Boiron SA | 198.7 Million EUR | -29.033% |
| Vetoquinol SA | 165.12 Million EUR | -55.273% |
| Valneva SE | 341.14 Million EUR | 24.844% |
| AB Science S.A. | 46.5 Million EUR | -451.281% |
| Nanobiotix S.A. | 95.74 Million EUR | -167.798% |
| PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -897.821% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -5538.663% |
| BioSenic S.A. | 32.26 Million EUR | -694.663% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -95.64% |
| Formycon AG | 387.61 Million EUR | 33.854% |